Arcellx (ACLX) Expected to Announce Quarterly Earnings on Thursday

Arcellx (NASDAQ:ACLX) is anticipated to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.13) per share and revenue of $6.0730 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.01) EPS for the quarter, meeting analysts’ consensus estimates of ($1.01). The business had revenue of $1.65 million during the quarter, compared to analyst estimates of $13.40 million. Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. On average, analysts expect Arcellx to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Arcellx Stock Performance

Shares of ACLX opened at $115.07 on Tuesday. The company has a 50-day simple moving average of $113.60 and a 200-day simple moving average of $88.06. The firm has a market capitalization of $6.73 billion, a P/E ratio of -28.27 and a beta of 0.25. Arcellx has a 52 week low of $47.86 and a 52 week high of $115.13.

Analyst Ratings Changes

ACLX has been the subject of a number of research analyst reports. Needham & Company LLC lowered shares of Arcellx from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. TD Cowen cut shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 2nd. William Blair cut shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 23rd. HC Wainwright cut shares of Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research note on Monday, February 23rd. Finally, Wells Fargo & Company cut shares of Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 target price on the stock. in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Arcellx has an average rating of “Hold” and an average price target of $111.87.

Insider Buying and Selling at Arcellx

In related news, insider Rami Elghandour sold 89,916 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the sale, the insider owned 276,051 shares in the company, valued at $31,447,729.92. This trade represents a 24.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 8.35% of the company’s stock.

Institutional Trading of Arcellx

Large investors have recently added to or reduced their stakes in the company. Twinbeech Capital LP bought a new stake in Arcellx during the fourth quarter worth about $453,000. Aquatic Capital Management LLC bought a new stake in Arcellx during the third quarter worth about $430,000. E Fund Management Co. Ltd. grew its stake in Arcellx by 15.1% during the second quarter. E Fund Management Co. Ltd. now owns 6,293 shares of the company’s stock worth $414,000 after buying an additional 825 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Arcellx by 105.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,143 shares of the company’s stock worth $405,000 after buying an additional 3,147 shares during the last quarter. Finally, Prudential Financial Inc. grew its stake in Arcellx by 49.2% during the second quarter. Prudential Financial Inc. now owns 4,900 shares of the company’s stock worth $323,000 after buying an additional 1,615 shares during the last quarter. 96.03% of the stock is owned by institutional investors.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.